Bath & Body Works (NYSE:BBWI) Issues Q2 2026 Earnings Guidance

Bath & Body Works (NYSE:BBWI) updated its second quarter 2026 earnings guidance on Wednesday. The company provided EPS guidance of 0.300-0.300 for the period, compared to the consensus EPS estimate of 0.200. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion. Bath & Body Works also updated its FY 2026 guidance to 2.400-2.650 EPS.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. TD Cowen decreased their price target on shares of Bath & Body Works from $26.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Bath & Body Works from $21.00 to $22.00 and gave the company a “hold” rating in a research note on Tuesday, March 3rd. UBS Group cut their target price on Bath & Body Works from $22.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 20th. Weiss Ratings reissued a “hold (c-)” rating on shares of Bath & Body Works in a research report on Monday, April 20th. Finally, Barclays boosted their target price on Bath & Body Works from $20.00 to $21.00 and gave the company an “equal weight” rating in a research report on Monday, March 2nd. Three research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company. According to MarketBeat, Bath & Body Works has a consensus rating of “Hold” and a consensus price target of $21.21.

Bath & Body Works Trading Up 0.1%

NYSE BBWI opened at $17.78 on Wednesday. The company’s 50-day moving average price is $18.67 and its 200-day moving average price is $20.26. The stock has a market cap of $3.58 billion, a PE ratio of 5.64, a PEG ratio of 1.77 and a beta of 1.43. Bath & Body Works has a 12 month low of $14.27 and a 12 month high of $33.96.

Bath & Body Works (NYSE:BBWI) last posted its quarterly earnings results on Wednesday, May 27th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.03. Bath & Body Works had a net margin of 8.90% and a negative return on equity of 45.60%. Bath & Body Works has set its Q2 2026 guidance at 0.300-0.300 EPS and its FY 2026 guidance at 2.400-2.650 EPS. As a group, sell-side analysts forecast that Bath & Body Works will post 2.61 earnings per share for the current year.

Bath & Body Works Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 19th. Shareholders of record on Friday, June 5th will be paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 4.5%. The ex-dividend date is Friday, June 5th. Bath & Body Works’s dividend payout ratio is currently 25.40%.

Hedge Funds Weigh In On Bath & Body Works

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Parallel Advisors LLC grew its position in shares of Bath & Body Works by 42.6% during the 4th quarter. Parallel Advisors LLC now owns 1,897 shares of the company’s stock worth $38,000 after buying an additional 567 shares in the last quarter. Meeder Asset Management Inc. grew its position in shares of Bath & Body Works by 28.5% during the 4th quarter. Meeder Asset Management Inc. now owns 2,874 shares of the company’s stock worth $58,000 after buying an additional 637 shares in the last quarter. State of Wyoming grew its position in shares of Bath & Body Works by 6.2% during the 2nd quarter. State of Wyoming now owns 11,294 shares of the company’s stock worth $338,000 after buying an additional 661 shares in the last quarter. Vident Advisory LLC grew its position in shares of Bath & Body Works by 2.8% during the 2nd quarter. Vident Advisory LLC now owns 25,229 shares of the company’s stock worth $756,000 after buying an additional 692 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its position in shares of Bath & Body Works by 217.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock worth $35,000 after buying an additional 801 shares in the last quarter. Institutional investors own 95.14% of the company’s stock.

Bath & Body Works Company Profile

Bath & Body Works, Inc is a leading specialty retailer focused on personal care, home fragrance and complementary products. Through its flagship Bath & Body Works brand, the company offers a diverse assortment of shower gels, lotions, fragrance mists, candles and home fragrance items. Its product portfolio also includes the White Barn Candle Co range of premium scented candles and diffusers. Bath & Body Works serves consumers through a combination of brick-and-mortar stores and e-commerce platforms, delivering seasonal collections, limited-edition releases and signature scent lines.

Founded in 1990 as part of Limited Brands (now L Brands), Bath & Body Works opened its first store in New Albany, Ohio, and quickly expanded across the United States.